Publicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (35)

2024

  1. Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis

    Diabetes Technology and Therapeutics, Vol. 26, Núm. 8, pp. 575-586

  2. Consenso del grupo de trabajo de los trastornos de la conducta alimentaria de SENPE (GTTCA-SENPE). Evaluación y tratamiento médico-nutricional en la anorexia nerviosa. Actualización 2023

    Nutricion hospitalaria, Vol. 41, Núm. 1, pp. 1-60

  3. Current barriers to initiating insulin therapy in individuals with type 2 diabetes

    Frontiers in Endocrinology, Vol. 15

  4. Nutritional and Morphofunctional Assessment of Post-ICU Patients with COVID-19 at Hospital Discharge: NutriEcoMuscle Study

    Nutrients, Vol. 16, Núm. 6

  5. Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort

    Viruses, Vol. 16, Núm. 3

  6. Urine beyond electrolytes: Diagnosis through extracellular vesicles

    Nefrologia

2023

  1. Expert Consensus on Morphofunctional Assessment in Disease-Related Malnutrition. Grade Review and Delphi Study

    Nutrients, Vol. 15, Núm. 3

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. How the COVID-19 pandemic has affected the training of Endocrinology and Nutrition Residents. Results of a survey by the Spanish Society of Endocrinology and Nutrition

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 3, pp. 219-226

2021

  1. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors

    Cancers, Vol. 12, Núm. 10, pp. 1-18

2019

  1. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329

2018

  1. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

    Scientific Reports, Vol. 8, Núm. 1

  2. Protocolo de diagnóstico y tratamiento de los trastornos del ciclo de la urea

    Protocolos de diagnóstico y tratamiento de los errores congénitos del metabolismo (Ergon), pp. 1-26

2017

  1. MKK6 controls T3-mediated browning of white adipose tissue

    Nature Communications, Vol. 8, Núm. 1

2016

  1. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

2010

  1. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2007

  1. Critical assessment of the current guidelines for the management and treatment of morbidly obese patients

    Journal of Endocrinological Investigation, Vol. 30, Núm. 10, pp. 844-852

1989

  1. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: Does acute hyperglycemia act through hypothalamic release of somatostatin?

    Neuroendocrinology, Vol. 49, Núm. 5, pp. 551-554

1987

  1. Fine needle aspiration biopsy in the diagnosis of thyroid cancer and thyroid disease

    Cancer, Vol. 59, Núm. 6, pp. 1206-1209